|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Select publications
Brufsky A. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: A Z-FAST update. Semin Oncol 2006;33(Suppl):13-7. Abstract
Buzdar AU, on behalf of the ATAC Trialists’ Group. Clinical features of joint symptoms observed in the ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial. Proc ASCO 2006;Abstract 551.
Coleman RE, on behalf of the ATAC Trialists’ Group. Effect of anastrozole on bone mineral density: 5-year results from the ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial. Proc ASCO 2006;Abstract 511.
Cuzick J et al. First results from the International Breast Cancer Intervention Study (IBIS-I): A randomized prevention trial. Lancet 2002;360:817-24. Abstract
Ettinger B et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 1999;282:637-45. Abstract
Fisher B et al. Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97(22):1652-62. Abstract
Fisher B et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90(18):1371-88. Abstract
Goss PE et al. Updated analysis of NCIC CTG MA.17 (letrozole vs placebo to letrozole vs placebo) post unblinding. San Antonio Breast Cancer Symposium 2005;Abstract 16.
Horton J. 1995 Oxford breast cancer overview — Preliminary outcomes. Cancer Control 1996;3:78-9. Abstract
Howell A, on behalf of the ATAC Trialists’ Group. Analysis of fracture risk factors from the ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial: 5-year data. Proc ASCO 2006;Abstract 563.
Jordan VC. Optimising endocrine approaches for the chemoprevention of breast cancer beyond the Study of Tamoxifen and Raloxifene (STAR) Trial. Eur J Cancer 2006;[Epub ahead of print]. Abstract
Land SR et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295(23):2742-51. Abstract
Paik S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24(23):3726-34. Abstract
Paik S. Methods for gene expression profiling in clinical trials of adjuvant breast cancer therapy. Clin Cancer Res 2006;12(3 Pt 2):1019s-23s. Abstract
Paik S et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26. Abstract
Veronesi U et al. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998;352(9122):93-7. Abstract
Vogel VG et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295(23):2727-41. Abstract
Wickerham CL et al. The study of tamoxifen and raloxifene (STAR): Initial findings from the NSABP P-2 breast cancer prevention study. Proc ASCO 2006;LBA5. Abstract
 |
 |
